We are live on ! Find out more
AKTX

Akari Therapeutics
AKTX

12 hedge funds and large institutions have $2.54M invested in Akari Therapeutics in 2020 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0% → 0% (-0%)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

37% less funds holding

Funds holding: 19 → 12 (-7)

60% less capital invested

Capital invested by funds: $6.34M → $2.54M (-$3.8M)

70% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 10

Holders
12
Holders Change
-7
Holders Change %
-36.84%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
3
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HF
HRT Financial
New York
+$71.2K
2
WS
Wedbush Securities
California
+$57.8K
3
HighTower Advisors
HighTower Advisors
Illinois
+$29.7K
4
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
+$20.8K
5
Morgan Stanley
Morgan Stanley
New York
+$8.9K

Top Sellers

Rank Fund Capital Flow
1
HP
Hikari Power
Japan
-$2.61M
2
Millennium Management
Millennium Management
New York
-$59K
3
Renaissance Technologies
Renaissance Technologies
New York
-$46K
4
Citadel Advisors
Citadel Advisors
Florida
-$41K
5
Squarepoint
Squarepoint
New York
-$41K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$787K – – –
OFW
2
Omnia Family Wealth
Florida
$681K – – –
UAS
3
United Asset Strategies
New York
$499K -$25.2K -17 -5%
Renaissance Technologies
4
Renaissance Technologies
New York
$189K -$46K -31 -19%
HP
5
Hikari Power
Japan
$156K -$2.61M -1,763 -94%
HF
6
HRT Financial
New York
$88K +$71.2K +48 +320%
WS
7
Wedbush Securities
California
$55K +$57.8K +39 New
HighTower Advisors
8
HighTower Advisors
Illinois
$27K +$29.7K +20 New
PNC Financial Services Group
9
PNC Financial Services Group
Pennsylvania
$21K – – –
Commonwealth Equity Services
10
Commonwealth Equity Services
Massachusetts
$18K +$20.8K +14 New
Morgan Stanley
11
Morgan Stanley
New York
$10K +$8.9K +6 +600%
Bank of America
12
Bank of America
North Carolina
$5K – – –
Millennium Management
13
Millennium Management
New York
– -$59K -34 Closed
Citadel Advisors
14
Citadel Advisors
Florida
– -$41K -24 Closed
Squarepoint
15
Squarepoint
New York
– -$41K -24 Closed
VF
16
Virtu Financial
New York
– -$40K -23 Closed
Envestnet Asset Management
17
Envestnet Asset Management
Illinois
– -$29K -17 Closed
PCG
18
Private Capital Group
Connecticut
– -$4.45K -3 Closed
TC
19
Truvestments Capital
Florida
– -$4K -3 Closed
Osaic Holdings
20
Osaic Holdings
Arizona
– -$1.48K -1 Closed
PFGIA
21
Patriot Financial Group Insurance Agency
Massachusetts
– -$2K -1 Closed
UBS Group
22
UBS Group
Switzerland
– -$1K -1 Closed

AKTX Hedge Fund Activity: Q3 2020 in Review

12 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q3 2020, worth a combined $2.54M — down 60% from $6.34M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of AKTX and 3 opened new positions — a net loss of 7 holders — while 3 trimmed existing stakes and 2 added.

The largest buyer was HRT Financial, adding an estimated $71.2K. The largest seller was Hikari Power, cutting an estimated $2.61M.

  • 12 institutional investors held Akari Therapeutics (AKTX) as of Q3 2020, down from 19 in Q2 2020.
  • Funds reported $2.54M of Akari Therapeutics stock for Q3 2020, down 60% quarter-over-quarter.
  • 3 funds opened new Akari Therapeutics positions in Q3 2020 and 10 closed out, a net change of -7 holders.
  • The largest Akari Therapeutics buyer in Q3 2020 was HRT Financial, an estimated $71.2K added.
  • The largest Akari Therapeutics seller in Q3 2020 was Hikari Power, an estimated $2.61M sold.

Based on aggregated 13F filings for Q3 2020.